Education
About Us
Working with TipRanks
Follow Us
Leap Therapeutics (LPTX)
:LPTX
Total Valuation
Leap Therapeutics has a market cap or net worth of ―. The enterprise value is ―.
Market Cap―
Enterprise Value―
Share Statistics
Leap Therapeutics has ― shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding―
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Leap Therapeutics’s return on equity (ROE) is -1.93 and return on invested capital (ROIC) is -200.12%.
Return on Equity (ROE)-1.93
Return on Assets (ROA)-1.38
Return on Invested Capital (ROIC)-200.12%
Return on Capital Employed (ROCE)-2.00
Revenue Per Employee―
Profits Per Employee-10.00T>
Employee Count―
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Leap Therapeutics is ―. Leap Therapeutics’s PEG ratio is 0.03.
PE Ratio―
PS Ratio0.00
PB Ratio3.09
Price to Fair Value3.09
Price to FCF-1.79
Price to Operating Cash Flow-1.90
PEG Ratio0.03
Income Statement
In the last 12 months, Leap Therapeutics had revenue of 0.00 and earned -67.56M in profits. Earnings per share was -1.81.
Revenue0.00
Gross Profit0.00
Operating Income-70.06M
Pretax Income-66.97M
Net Income-67.56M
EBITDA-70.05M
Earnings Per Share (EPS)-1.81
Cash Flow
In the last 12 months, operating cash flow was -60.77M and capital expenditures -1.99M, giving a free cash flow of -62.76M billion.
Operating Cash Flow-60.77M
Free Cash Flow-62.76M
Free Cash Flow per Share-10.00T>
Dividends & Yields
Leap Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta―
52-Week Price Change-21.11%
50-Day Moving Average0.80
200-Day Moving Average0.47
Relative Strength Index (RSI)63.88
Average Volume (3m)―
Important Dates
Leap Therapeutics upcoming earnings date is Mar 23, 2026, TBA (Confirmed).
Last Earnings DateNov 12, 2025
Next Earnings DateMar 23, 2026
Ex-Dividend Date―
Financial Position
Leap Therapeutics as a current ratio of 3.41, with Debt / Equity ratio of 0.68%
Current Ratio3.41
Quick Ratio3.41
Debt to Market Cap0.00
Net Debt to EBITDA0.67
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Leap Therapeutics has paid 585.00K in taxes.
Income Tax585.00K
Effective Tax Rate>-0.01
Enterprise Valuation
Leap Therapeutics EV to EBITDA ratio is -0.87, with an EV/FCF ratio of -1.01.
EV to Sales0.00
EV to EBITDA-0.87
EV to Free Cash Flow-1.01
EV to Operating Cash Flow-1.01
Balance Sheet
Leap Therapeutics has $9.69M in cash and marketable securities with $38.00K in debt, giving a net cash position of $9.65M billion.
Cash & Marketable Securities$9.69M
Total Debt$38.00K
Net Cash$9.65M
Net Cash Per Share$10.00T>
Tangible Book Value Per Share$0.93
Margins
Gross margin is 50.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin50.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Leap Therapeutics is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast36.27%